Takeda Pharmaceutical Company Limited announced that results from the primary endpoint analysis of the ongoing pivotal Phase III Tetravalent Immunization...
Takeda Pharmaceutical Company Limited announced that it has vaccinated the first subject in the Tetravalent Immunization against Dengue Efficacy Study...
The European Commission has granted marketing authorization for Dengvaxia, Sanofi's dengue vaccine. The marketing authorization follows the 18 October 2018,...
Sanofi Pasteur, the vaccines division of Sanofi announced that the final landmark phase III efficacy study of its Dengue vaccine...
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the marketing...
Takeda announced that the European Commission (EC) granted marketing authorization for the company’s dengue vaccine Qdenga (Dengue Tetravalent Vaccine) or TAK 003, for the prevention of dengue disease in individuals from four years of age in the European Union (EU)
Takeda announced that the FDA has accepted and granted priority review of the Biologics License Application (BLA) for TAK 003, the company’s investigational dengue vaccine candidate
Sanofi Pasteur, the vaccines division of Sanofi has announced the publication in The Lancet of the detailed results of its...
Takeda Pharmaceutical Company Limited announced that its dengue vaccine candidate (TAK-003) demonstrated continued protection against dengue illness and hospitalization, regardless of an individual’s previous dengue exposure, with no important safety risks identified through three years after vaccination in the ongoing pivotal Phase III Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial.
The FDA approved Dengvaxia (Dengue Tetravalent Vaccine, Live), from Sanofi Pasteur, for the prevention of dengue disease caused by serotypes...